$0.15
(Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
7.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.7
-
Debt to Equity
-0.7
-
Book Value
$--
-
EPS
$-2.5
-
Face value
--
-
Shares outstanding
2,676,637
8 Years Aggregate
CFO
$-187.35 Mln
EBITDA
$-192.24 Mln
Net Profit
$-186.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vaccinex (VCNX)
| -- | -- | -- | -- | -74.0 | -72.8 | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Vaccinex (VCNX)
| -89.2 | -93.2 | -38.5 | -49.8 | -57.3 | 33.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vaccinex (VCNX)
|
0.8 | 2.7 | 2.1 | -5.3 | -2,075.4 | 104.4 | -- | 7.3 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Vaccinex (VCNX)
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a... humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York. Read more
-
Co-Founder, CEO, President & Director
Dr. Maurice Zauderer Ph.D.
-
Co-Founder, CEO, President & Director
Dr. Maurice Zauderer Ph.D.
-
Headquarters
Rochester, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vaccinex (VCNX)
What is the current share price of Vaccinex Inc (VCNX) Today?
The share price of Vaccinex Inc (VCNX) is $0.75 (NASDAQ) as of 01-Sep-2026 11:11 EDT. Vaccinex Inc (VCNX) has given a return of -73.99% in the last 3 years.
What is the current PB & PE ratio of Vaccinex Inc (VCNX)?
Since, TTM earnings of Vaccinex Inc (VCNX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-0.14 |
-1.05 |
2023 |
-0.03 |
-0.25 |
2022 |
-0.01 |
0.03 |
2021 |
-0.01 |
0.02 |
What is the 52 Week High and Low of Vaccinex Inc (VCNX)?
The 52-week high and low of Vaccinex Inc (VCNX) are Rs 0.75 and Rs 0.75 as of 02-Sep-2026.
What is the market cap of Vaccinex Inc (VCNX)?
Vaccinex Inc (VCNX) has a market capitalisation of $ 3 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Vaccinex Inc (VCNX)?
Before investing in Vaccinex Inc (VCNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.